Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

NCT06697366 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Irinotecan liposome injection Ⅱ
DRUG: Sintilimab

Sponsor

Ruijin Hospital